The U.S. Food and Drug Administration has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for these drugs.
Similar Posts
Broselow Pediatric Emergency Rainbow Tape Recall: AirLife Removes Certain Broselow Pediatric Emergency Rainbow Tapes due to Misprinted Information
Certain Broselow Pediatric Emergency Rainbow Tapes were manufactured with incorrect information on the tape.Compounding when Drugs are on FDA’s Drug Shortages List
FDA understands that when a drug is in shortage, patients and health care professionals may look to compounded drugs as an option to get the medication they need.Quality and Regulatory Predictability: Shaping USP Standards – 12/11/2025
This discussion will show how USP public standards strengthen quality, streamline development, support regulatory compliance, and overall, increase regulatory predictability for drugs.Rhino 11 Gummy may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Rhino 11 Gummy, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.Alembic Pharmaceuticals Limited – 11/10/2021
Alembic Pharmaceuticals Limited – 11/10/2021. Country: India. Record Type: 483Intercos Europe S.p.A – 682273 – 08/15/2024
CGMP/Finished Pharmaceuticals/Adulterated